Similar articles

• Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.

  Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Rodgers GP, et al. N Engl J Med. 1993 Jan 14;328(2):73-80. doi: 10.1056/NEJM199301143280201. N Engl J Med. 1993. PMID: 7677965
• Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

  Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Loukopoulos D, et al. Blood Cells Mol Dis. 2000 Oct;26(5):453-66. doi: 10.1006/bcmd.2000.0328. Blood Cells Mol Dis. 2000. PMID: 11112383 Clinical Trial.
• Hydroxyurea therapy in thalassemia.

  Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N. Loukopoulos D, et al. Ann N Y Acad Sci. 1998 Jun 30;850:120-8. doi: 10.1111/j.1749-6632.1998.tb10469.x. Ann N Y Acad Sci. 1998. PMID: 9668534 Clinical Trial.
• Reactivation of fetal hemoglobin in patients with beta-thalassemia.

  Olivieri NF. Olivieri NF. Semin Hematol. 1996 Jan;33(1):24-42. Semin Hematol. 1996. PMID: 8714583 Review. No abstract available.
• Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.

  Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Musallam KM, et al. Blood. 2013 Mar 21;121(12):2199-212; quiz 2372. doi: 10.1182/blood-2012-10-408021. Epub 2013 Jan 11. Blood. 2013. PMID: 23315167 Review.